CryoPort Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,100.50
2,659.90
3,935.30
8,164.30
11,954.30
19,626.50
Cost of Goods Sold (COGS) incl. D&A
1,587.80
2,223.00
2,766.40
4,804.90
5,987.80
9,386.20
Gross Income
487.30
437.00
1,168.90
3,359.50
5,966.40
10,240.30
SG&A Expense
5,837.20
5,515.30
6,762.00
11,548.80
13,858.90
18,884.90
EBIT
6,324.50
5,078.40
5,593.00
8,189.30
7,892.50
8,644.60
Unusual Expense
16.50
13,692.90
-
4,195.30
-
-
Non Operating Income/Expense
-
8.10
4.30
1,400.90
14.30
821.80
Interest Expense
72.90
784.50
1,428.00
77.60
15.70
69.30
Pretax Income
6,380.80
19,563.80
7,025.30
13,863.10
7,893.90
9,535.60
Income Tax
1.60
1.60
1.60
7.60
5.10
20
Consolidated Net Income
6,382.40
19,565.40
7,026.90
13,870.70
7,899.00
9,555.60
Net Income
6,382.40
19,565.40
7,026.90
13,870.70
7,899.00
9,555.60
Net Income After Extraordinaries
6,382.40
19,565.40
7,026.90
13,870.70
7,899.00
9,555.60
Net Income Available to Common
6,382.40
19,565.40
12,196.50
13,870.70
7,899.00
9,555.60
EPS (Basic)
2.04
4.80
13.62
0.90
0.34
0.34
Basic Shares Outstanding
3,146.70
4,070.90
895.60
15,393.40
22,963.40
28,210.60
EPS (Diluted)
2.03
4.81
13.62
0.90
0.34
0.34
Diluted Shares Outstanding
3,146.70
4,070.90
895.60
15,393.40
22,963.40
28,210.60
EBITDA
5,930.50
4,766.80
5,395.10
7,787.60
7,227.70
7,786.70
Preferred Dividends
-
-
5,169.60
-
-
-

About CryoPort

View Profile
Address
17305 Daimler Street
Irvine California 92614
United States
Employees -
Website http://www.cryoport.com
Updated 07/08/2019
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures.